NEWS & EVENTS
Relevant News
Science Behind the Silent Killer
The science behind the silent killer. Here is how Inimmune is developing vaccines to help solve the opioid epidemic. Read full article: Science and the Silent Killer
Bioscience research and development can unlock the economic potential of the Mountain West
Bioscience research and development can unlock the economic potential of the Mountain West, providing jobs and substantial economic benefit. Read how Inimmune Corporation in Missoula, Montana...
Vaccine targeting opioid addiction with Dr. Jay Evans
The University of Montana is a recipient of a $3.3 million dollar contract from the National Institutes of Health to develop a vaccine to treat opioid addiction. Inimmune Corporation will be a...
The Future of Food Allergies – Developing New Treatments
Inimmune is developing vaccines to treat food allergies. Read about the future prospects of treatments for food allergies here....
University of Montana disease treatment research center pulls in $22 million in grants
Original Article by https://missoulian.com/users/profile/KeilaSzpaller October, 9, 2018 A research center at the University of Montana earned $22.4 million this summer and fall...
Inimmune Receives $1M SBIR Phase II Grant
Montana biotech company receives Small Business Innovation Research Grant to develop novel treatments against infectious diseases. Inimmune Corporation, a biotechnology company located in Missoula,...
Missoula’s Inimmune receives $600K to develop novel treatments for seasonal allergies
Missoula-based Inimmune Corp. has received a nearly $600,000 federal grant to identify and advance novel treatments for seasonal allergies. In an announcement Wednesday, the biotechnology firm...
Inimmune named one of the top 8 Montana startups to watch
Originally written by DAVID ERICKSON (david.erickson@missoulian.com) and reported in the Missoulian. Three Missoula companies and two others in western Montana have made the Montana High...
Upcoming Events
Upcoming Events
Look for us at these upcoming conferences. If you are interested in scheduling a face to face meeting during one of these conferences please use the contact button
BIO International – June 2020
Relevant Publications
Smith AJ, Li Y, Bazin-Lee H, St-Jean JR, Larocque D, Baldridge J. Evaluation of novel synthetic TLR7/8 agonists as human vaccine adjuvants. Vaccine. 2016. [Epub ahead of print].
Oberoi, H.; Yorgensen, Y.; Evans, J.; Burkhart, D.; PEG modified liposomes in combination with methylglycol chitosan enhances the murine sublingual immune response to influenza vaccination Journal of Controlled Release, Vol 223, 10 Feb 2016.
Spinner, J.; Oberoi, H.; Yorgensen, Y.; Burkhart, D.; Evans, J.; Methylglycol chitosan and a synthetic TLR4 agonist enhance immune responses to influenza vaccine administered sublingually Vaccine, Volume 33, pages5845-5853, 2015.
Khalaf, W. S. Bowen, H.G. Bazin , K.T. Ryter, M.T. Livesay, J.R. Ward, J.T. Evans, D.A. Johnson, “Characterization of TRIF selectivity in the AGP class of lipid A mimetics: Role of secondary lipid chains”, Bioorg. Med. Chem. Lett., 25, 547-533, 2015
H.G. Bazin, Y. Li, J.K. Khalaf , S. Mwakwari, M.T. Livesay, J.T. Evans, D.A. Johnson, “Structural requirements for TLR7-selective signaling by 9-(4-piperidinylalkyl)-8-oxoadenine derivatives”, Bioorg. Med. Chem. Lett., 25, 1318-1323, 2015
H.G. Bazin, L.S. Bess, M.T. Livesay, D.A. Johnson, “Phospholipidation of TLR7/8-active imidazoquinolines using a tandem phosphoramidite method”, Tetrahedron Lett, 57, 2063-2066, 2016
Mwakwari, L.S. Bess, H.G. Bazin, D.A. Johnson, “Efficient tin-mediated synthesis of lysophospholipid conjugates of a TLR7/8-active imidazoquinoline”, Tetrahedron Lett, 57, 2093-2096, 2016